The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Experience of patients with HIV and squamous cell carcinoma of the anal canal (SCAC) treated with retifanlimab.
 
Jean-Philippe Spano
Consulting or Advisory Role - AstraZeneca; Exact Sciences; Gilead Sciences; Incyte; Lilly; MSD; Novartis; Pfizer; Pierre Fabre; Roche
Research Funding - Incyte; Leo Pharma; MSD Avenir
 
Jaume Capdevila
Consulting or Advisory Role - Advanced Accelerator Applications; Bayer; Eisai; Esteve; Exelixis; Ipsen; Isotopen Technologien; Lilly; Merck Serono; Novartis; Pfizer; Roche/Genentech; Sanofi
Speakers' Bureau - Bayer; Eisai; Esteve; Hutchison MediPharma; Ipsen; Isotopen Technologien; Lilly; Merck Serono; Novartis; Pfizer; Sanofi
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Eisai (Inst); Gilead Sciences (Inst); Ipsen (Inst); Ipsen (Inst); ITM Solucin (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Eisai; Gilead Sciences; Ipsen; Pfizer
 
Frank Van Fraeyenhove
No Relationships to Disclose
 
Sara Lonardi
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Beigene; Bristol-Myers Squibb; Daiichi Sankyo; Fosun Pharma; GlaxoSmithKline; Incyte; Lilly; Merck Serono; MSD; Nimbus Therapeutics; Rottapharm Biotech; SERVIER; Takeda
Speakers' Bureau - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Incyte; Lilly; Merck Serono; MSD Oncology; Pierre Fabre; Roche; Servier
Research Funding - Amgen; AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck Serono; Roche (Inst)
 
Federica Morano
Honoraria - Accademia Nazionale Di Medicina (ACCMED); Pierre Fabre; SERVIER
Research Funding - Incyte (Inst)
Travel, Accommodations, Expenses - Amgen; Daiichi Sankyo/Astra Zeneca; Pierre Fabre; SERVIER
 
Monica Guillot
Consulting or Advisory Role - GlaxoSmithKline; Roche
Speakers' Bureau - Merck KGaA; Roche
Travel, Accommodations, Expenses - Amgen; SERVIER
 
Pauline Rochefort
Consulting or Advisory Role - SERVIER
Travel, Accommodations, Expenses - Amgen; Sanofi; SERVIER
 
Michel Ducreux
Employment - Sandoz (I)
Honoraria - Bayer; Pierre Fabre; Roche/Genentech; TERUMO
Consulting or Advisory Role - Abbvie (Inst); Abcely; Amgen; Astellas Pharma; AstraZeneca; Basilea; Bayer; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; HalioDx; Ipsen; Lilly; Merck Serono; MSD; Novartis; Pierre Fabre; Rafael Pharmaceuticals; Roche; Scandion Oncology; Servier; Sotio; Zymeworks
Speakers' Bureau - Amgen; AstraZeneca; Bayer; GlaxoSmithKline; HalioDx; Lilly; Merck KGaA; MSD; Pierre Fabre; Roche; SERVIER
Research Funding - Keocyt (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bayer; Merck Serono; Pierre Fabre; Roche; SERVIER
 
Anderley Gordon
Honoraria - SERVIER
 
Ludovic Evesque
Honoraria - AstraZeneca; Merck; SERVIER
 
Edward Kim
Consulting or Advisory Role - Relay Therapeutics
Speakers' Bureau - Eisai; Seagen
Research Funding - Astellas Pharma (Inst); EpicentRx (Inst); ERYTECH Pharma (Inst); Eureka Therapeutics (Inst); Fibrogen (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Merck (Inst); NGM BIOPHARMACEUTICALS (Inst)
 
Mark Jones
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Chuan Tian
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Mihaela Munteanu
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Aurore Vozy
No Relationships to Disclose
 
Duncan Gilbert
No Relationships to Disclose